Gleevec Study for Patients With Ovarian Cancer

Summary

Primary Objectives: 1. To determine the efficacy of Gleevec in patients with recurrent platinum-resistant, taxane-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer whose tumor expresses either c-KIT, platelet-derived growth factor receptor (PDGRF), or ABL. 2. To determine the nature and degree of toxicity of Gleevec in this cohort of patients.

Timeline

Start

2002-03

Primary completion

2012-02

Completion

2012-02

Drugs

Indications